Shiga toxin-associated hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Distinct mechanisms of pathogenesis

Kidney International

Volumn 75, Issue SUPPL. 112, 2009, Pages

  Tarr, Phillip I ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bloody diarrhea; E. coli O157:H7; Hemolytic uremic syndrome; Optimal therapy; Shiga toxin; Thrombotic thrombocytopenic purpura

Indexed keywords

FIBRIN; SHIGA TOXIN; SORBITOL; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ABDOMINAL PAIN; AGAR MEDIUM; ANTIBODY RESPONSE; BLOODY DIARRHEA; CELL SWELLING; CHILDHOOD DISEASE; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ENDOTHELIUM INJURY; FECES ANALYSIS; FIBRIN DEPOSITION; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HISTOPATHOLOGY; HUMAN; INFECTION COMPLICATION; INTESTINE INFECTION; KIDNEY FAILURE; MICROANGIOPATHY; MICROBIOLOGY; NEUROLOGIC DISEASE; PAINFUL DEFECATION; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RISK ASSESSMENT; SCREENING; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT INDICATION; ANIMAL; BLOOD COMPONENT THERAPY; DIARRHEA; ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI O157; FECES; METABOLISM; MICROBIOLOGICAL EXAMINATION; PATHOGENICITY; REVIEW;

ABDOMINAL PAIN; ANIMALS; BACTERIOLOGICAL TECHNIQUES; BLOOD COMPONENT TRANSFUSION; DIAGNOSIS, DIFFERENTIAL; DIARRHEA; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI O157; FECES; HEMOLYTIC-UREMIC SYNDROME; HUMANS; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SHIGA TOXINS;

EID: 63049126329     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.615     Document Type: Conference Paper

References (33)

1. Ake JA, Jelacic S, Ciol MA et al. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics 2005; 115: e673-e680.
2. Chandler WL, Jelacic S, Boster DR et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002; 346: 23-32.
3. Wong CS, Jelacic S, Habeeb RL et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000; 342: 1930-1936.
4. Havens PL, Hoffman GM, Shith KJ. The homogeneous nature of the hemolytic uremic syndrome. Clin Pediatr (Phila) 1989; 28: 482-483.
5. Katz J, Lurie A, Kaplan BS et al. Coagulation findings in the hemolytic-uremic syndrome of infancy: similarity to hyperacute renal allograft rejection. J Pediatr 1971; 78: 426-434.
6. Fey PD, Wickert RS, Rupp ME et al. Prevalence of non-O157:H7 Shiga toxin-producing Escherichia coli in diarrheal stool samples from Nebraska. Emerg Infect Dis 2000; 6: 530-533.
7. Klein EJ, Stapp JR, Clausen CR et al. Shiga toxin-producing Escherichia coli in children with diarrhea: a prospective point-of-care study. J Pediatr 2002; 141: 172-177.
8. Carroll KC, Adamson K, Korgenski K et al. Comparison of a commercial reversed passive latex agglutination assay to an enzyme immunoassay for the detection of Shiga toxin-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 2003; 22: 689-692.
9. Teel LD, Daly JA, Jerris RC et al. Rapid detection of Shiga toxin-producing Escherichia coli by optical immunoassay. J Clin Microbiol 2007; 45: 3377-3380.
10. Park CH, Kim HJ, Hixon DL et al. Evaluation of the duopath verotoxin test for detection of Shiga toxins in cultures of human stools. J Clin Microbiol 2003; 41: 2650-2653.
11. Melnyk AM, Solez K, Kjellstrand CM. Adult hemolytic-uremic syndrome. A review of 37 cases. Arch Intern Med 1995; 155: 2077-2084.
12. Brandt JR, Fouser LS, Watkins SL et al. Escherichia coli O157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. J Pediatr 1994; 125: 519-526.
13. Miceli S, Jure MA, de Saab OA et al. A clinical and bacteriological study of children suffering from haemolytic uraemic syndrome in Tucuman, Argentina. Jpn J Infect Dis 1999; 52: 33-37.
14. Tarr PI, Neill MA, Clausen CR et al. Escherichia coli O157:H7 and the hemolytic uremic syndrome: importance of early cultures in establishing the etiology. J Infect Dis 1990; 162: 553-556.
15. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365: 1073-1086.
16. Tsai HM, Chandler WL, Sarode R et al. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Res 2001; 49: 653-659.
17. Bell WR, Braine HG, Ness PM et al. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991; 325: 398-403.
18. Upadhyaya K, Barwick K, Fishaut M et al. The importance of nonrenal involvement in hemolytic-uremic syndrome. Pediatrics 1980; 65: 115-120.
19. Inward CD, Howie AJ, Fitzpatrick MM et al. Renal histopathology in fatal cases of diarrhoea-associated haemolytic uraemic syndrome. British Association for Paediatric Nephrology. Pediatr Nephrol 1997; 11: 556-559.
20. Richardson SE, Karmali MA, Becker LE et al. The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. Hum Pathol 1988; 19: 1102-1108.
21. Habib R. Pathology of the hemolytic uremic syndrome. In: Kaplan BS, Trompeter RS, Moake JL (eds). Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. Marcel Dekker: New York, 1992, pp 315-353.
22. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594.
23. Furlan M, Robles R, Galbusera M et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-1584.
24. Levy GG, Nichols WC, Lian EC et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
25. Tsai HM. Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes. J Thromb Haemost 2003; 1: 625-631.
26. Veyradier A, Obert B, Haddad E et al. Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome. J Pediatr 2003; 142: 310-317.
27. Hunt BJ, Lammle B, Nevard CH et al. von Willebrand factor-cleaving protease in childhood diarrhoea-associated haemolytic uraemic syndrome. Thromb Haemost 2001; 85: 975-978.
28. Karpac CA, Li X, Terrell DR et al. Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison. Br J Haematol 2008; 141: 696-707.
29. Lammle B, Hunt BJ, Haycock GB et al. von Willebrand factor-cleaving protease in childhood diarrhoea-associated haemolytic uraemic syndrome. Thromb Haemost 2002; 87: 549-550.
30. Desch K, Motto D. Is there a shared pathophysiology for thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome? J Am Soc Nephrol 2007; 18: 2457-2460.
31. Chauhan AK, Walsh MT, Zhu G et al. The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis. Blood 2008; 111: 3452-3457.
32. Shaz BH, Linenberger ML, Bandarenko N et al. Category IV indications for therapeutic apheresis: ASFA fourth special issue. J Clin Apher 2007; 22: 176-180.
33. Pollock KG, Young D, Beattie TJ et al. Clinical surveillance of thrombotic microangiopathies in Scotland, 2003-2005. Epidemiol Infect 2008; 136: 115-121.